GSK3B and nonpapillary renal cell carcinoma: To further confirm the participation of EGFR/AKT/GSK3β into shATF3 promoted ccRCC progression, we applied AKT inhibitor or GSK3β inhibitor to examine whether it can block the biological functionalities of ATF3.